Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
Tranexamic acid promotes the clotting of blood and
thereby reduces bleeding due to tooth extractions in people with hemophilia.
People with hemophilia bleed easily because they lack a specific blood protein
necessary for forming blood clots.
Tranexamic acid is a man-made amino acid derivative that increases blood
clotting by preventing the breakdown of fibrin. Fibrin is a protein and an
important component of blood clots. It is broken down by another protein called
plasmin. Tranexamic acid blocks the action of plasmin on fibrin and thereby
prevents the breakdown of fibrin. This leads to stabilization and preservation
of fibrin in blood clots. This helps reduce bleeding after a tooth extraction.
The FDA approved tranexamic acid injection in December, 1986.